Statement: United States Food and Drug Administration Approves Teva’s Generic Epinephrine Injection

Teva is pleased with the US FDA’s approval of its generic AB-rated/therapeutically equivalent version of EpiPen® (epinephrine injection, USP) Auto-Injector 0.3 mg and 0.15 mg in the US.

Today’s approval marks an important step forward in bringing patients an additional option for the emergency treatment of allergic reactions and furthers our commitment to accessibility to quality products for the patients who need them,” said Brendan O’Grady, Executive Vice President and Head of North America.

The company is applying its full resources to this important launch in the coming months and is eager to begin supplying the market.


Source: Teva Pharmaceutical Industries Ltd.
Teva Pharmaceutical Industries Ltd.
IR Contacts
United States
Kevin C. Mannix, 215-591-8912
Ran Meir, 215-591-3033
or
Israel
Tomer Amitai, 972 (3) 926 7656
or
PR Contacts
United States
Kelley Dougherty, 973-658-0237
Elizabeth DeLuca, 267-468-4329
or
Israel
Yonatan Beker, 972 (54) 888 5898